Food Allergy Therapeutics Market Size in the 7Mm was ~USD 1,648 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight's "Food Allergy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the food allergy, historical and forecasted epidemiology and the food allergy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Food Allergy Market with DelveInsight's In-Depth Report @ Food Allergy Market Size [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Food Allergy Market Report

* In December 2024:- Novartis Pharmceuticals- Participants will receive up to 3 years treatment with ligelizumab after which they will enter a follow-up period for 16 weeks. During the study, participants will undergo allergy testing by a Skin Prick Test and Oral Food challenge to test if the treatment is working or not. Accordingly, this study will generate data that should provide guidance relative to the long-term (chronic) use of ligelizumab in food allergic patients in terms of safety, efficacy, pharmaco-dynamics, biomarkers and Qualify of Life, and potential discontinuation from treatment.
* In December 2024:- DBV Technologies- The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
* DelveInsight's analyst estimate that approximately 57.5 million Prevalent Cases of Food Allergy were found in 2023 in the 7MM.
* The United States exhibited the highest diagnosed prevalent population of food allergy, as compared to other 7MM countries. As per DelveInsight's estimations, the Total Prevalent Cases of Food Allergy in the US was around 33.1 million in 2023 and is projected to increase during the forecast period owing to the increasing awareness among the patient population and launch of novel therapies.
* According to DelveInsight's estimates, the Total Prevalent Cases of Food Allergy in EU4 and the UK were found to be ~16.9 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries, except for Germany, where the cases are expected to decrease. The highest proportion of Food Allergy cases was reported in Spain among the EU4 countries, while the least number of cases was found in the UK.
* The estimates show the Total Prevalent Cases of Food Allergy in Japan was found to be around 7.4 million in 2023, which is estimated to decrease by 2034.
* In the US, food allergy cases were classified by specific causes such as Cow Milk, Peanut, Eggs, Wheat, Treenuts, Fish, Shellfish, Soy, and Others. Shellfish accounted for the most prevalent cases, approximately 8 million, in 2023.
* According to the analysis performed by DelveInsight's experts, the Age-specific Cases of Food Allergy were categorized into Children, and Adults. The higher number of cases (~28 million) was accounted for by the Adults in 2023 in the US.
* The leading Food allergy Companies such as Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
* Promising Food allergy Therapies such as Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.

Stay ahead in the Food Allergy Therapeutics Market with DelveInsight's Strategic Report @ Food Allergy Market Outlook [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Food Allergy Epidemiology Segmentation in the 7MM

* Food Allergy Prevalent cases
* Prevalent Cases of Food Allergy based on Etiology-specific Factors
* Food Allergy Age-specific Prevalence Cases

Download the report to understand which factors are driving Food Allergy epidemiology trends @ Food Allergy Prevalence [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Food Allergy Marketed Drugs

* Palforzia: Aimmune Therapeutics, Inc.

Approved in 2020, Palforzia is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, resulting in the ability to mitigate allergic reactions to the allergen over time. Palforiza is the first approved treatment for patients with peanut allergy. It is oral immunotherapy indicated to mitigate allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy.

Food Allergy Emerging Drugs

* Ligelizumab: Novartis Pharmaceuticals

Ligelizumab (QGE031), a humanized anti-IgE antibody developed by Novartis, is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. It is also directed against C3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139pM (as compared to the KD of omalizumab, ~6-8 nm). Ligelizumab's mechanism of action involves blocking the IgE/FcRI pathway, a key driver of the inflammatory process in CSU (chronic spontaneous urticaria), and binding with high affinity to the C3 domain of IgE.

* Viaskin Peanut: DBV Technologies

Viaskin Peanut is the first epicutaneous immunotherapy (EPIT) in development that leverages the skin to activate the immune system and induce desensitization in peanut-allergic children. EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system. By delivering the allergen directly to the lymph node through the Langerhans cells, pre-clinical research has shown that EPIT activates specific regulatory T cells (Tregs) that can down-regulate the Th2-oriented reaction to the allergen.

Get In-Depth Knowledge on Food Allergy Market Trends and Forecasts with DelveInsight @ Food Allergy Treatment Market [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Food Allergy Market Outlook

Food allergy has a diverse treatment classification associated with the disease landscape. The management of food allergy primarily revolves around the utilization of Epinephrine, Anti-histamines, Steroids, Beta-2-agonists, and Palforzia as needed. Palforzia is the major revenue generator in the current treatment landscape. The Food Allergy market is expected to experience positive growth with the approval of potential drugs like Ligelizumab (QGE031), Viaskin Peanut, Omalizumab, and others.

Food Allergy Market Dynamics

The Food Allergy market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies by major key players in the treatment regime. The launch of various multiple-stage pipeline products will significantly revolutionize the Food Allergy market dynamics shortly. The emerging drug analysis along with their detailed profiling is done by the DelveInsight.

Unlock Strategic Insights with DelveInsight's Comprehensive Food Allergy Market Report @ Food Allergy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Food Allergy Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Food Allergy Companies- Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
* Food allergy Therapies- Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.
* Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies
* Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers
* Food Allergy Unmet Needs, KOL's views, Analyst's views, Food Allergy Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Food Allergy Market Overview at a Glance

4 Methodology of Food Allergy Epidemiology and Market

5 Executive Summary of Food Allergy

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Drugs

12 Food Allergy: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=food-allergy-therapeutics-market-size-in-the-7mm-was-usd-1648-million-in-2023-is-expected-to-grow-by-2034-and-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market



This release was published on openPR.